My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 680

    1.

    Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.

    Fleischmann R, Tannenbaum H, Patel NP, Notter M, Sallstig P, Reginster JY.

    BMC Musculoskelet Disord. 2008 Mar 7;9:32.PMID: 18328090 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].

    Wittenberg RH, Schell E, Krehan G, Maeumbaed R, Runge H, Schlüter P, Fashola TO, Thurston HJ, Burger KJ, Trechsel U.

    Arthritis Res Ther. 2006;8(2):R35. Epub 2006 Jan 16.PMID: 16469112 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.

    Fleischmann R, Sheldon E, Maldonado-Cocco J, Dutta D, Yu S, Sloan VS.

    Clin Rheumatol. 2006 Feb;25(1):42-53. Epub 2005 Aug 13.PMID: 16132165 [PubMed - indexed for MEDLINE]Related articles

    4.

    Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.

    Sheldon E, Beaulieu A, Paster Z, Dutta D, Yu S, Sloan VS.

    Clin Ther. 2005 Jan;27(1):64-77.PMID: 15763607 [PubMed - indexed for MEDLINE]Related articles

    5.

    Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib.

    Lehmann R, Brzosko M, Kopsa P, Nischik R, Kreisse A, Thurston H, Litschig S, Sloan VS.

    Curr Med Res Opin. 2005 Apr;21(4):517-26.PMID: 15899100 [PubMed - indexed for MEDLINE]Related articles

    6.

    A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients.

    Stricker K, Yu S, Krammer G.

    BMC Musculoskelet Disord. 2008 Sep 8;9:118.PMID: 18778469 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.

    Tannenbaum H, Berenbaum F, Reginster JY, Zacher J, Robinson J, Poor G, Bliddal H, Uebelhart D, Adami S, Navarro F, Lee A, Moore A, Gimona A.

    Ann Rheum Dis. 2004 Nov;63(11):1419-26. Epub 2004 Feb 27.PMID: 15020310 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.

    Dougados M, Moore A, Yu S, Gitton X.

    Arthritis Res Ther. 2007;9(1):R11.PMID: 17266764 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis.

    Dahlberg LE, Holme I, Høye K, Ringertz B.

    Scand J Rheumatol. 2009 Mar-Apr;38(2):133-43.PMID: 19165648 [PubMed - indexed for MEDLINE]Related articles

    10.

    Long-term efficacy and safety of lumiracoxib 100 mg: an open-label extension of a 13-week randomized controlled trial in patients with primary osteoarthritis of the knee.

    Sheldon EA, Beaulieu A, Paster Z, Yu S, Rebuli R.

    Clin Exp Rheumatol. 2008 Jul-Aug;26(4):611-9.PMID: 18799092 [PubMed - indexed for MEDLINE]Related articles

    11.

    Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults.

    Kivitz A, Fairfax M, Sheldon EA, Xiang Q, Jones BA, Gammaitoni AR, Gould EM.

    Clin Ther. 2008 Dec;30(12):2366-77.PMID: 19167595 [PubMed - indexed for MEDLINE]Related articles

    12.

    Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.

    Sieper J, Klopsch T, Richter M, Kapelle A, Rudwaleit M, Schwank S, Regourd E, May M.

    Ann Rheum Dis. 2008 Mar;67(3):323-9. Epub 2007 Jul 6.PMID: 17616556 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

    Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS.

    JAMA. 2000 Sep 13;284(10):1247-55.PMID: 10979111 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority study.

    Emery P, Koncz T, Pan S, Lowry S.

    Clin Ther. 2008 Jan;30(1):70-83.PMID: 18343244 [PubMed - indexed for MEDLINE]Related articles

    15.

    Lumiracoxib 400 mg compared with celecoxib 400 mg and placebo for treating pain following dental surgery: a randomized, controlled trial.

    Fricke J, Davis N, Yu V, Krammer G.

    J Pain. 2008 Jan;9(1):20-7. Epub 2007 Oct 15.PMID: 17933588 [PubMed - indexed for MEDLINE]Related articles

    16.

    Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand.

    Grifka JK, Zacher J, Brown JP, Seriolo B, Lee A, Moore A, Gimona A.

    Clin Exp Rheumatol. 2004 Sep-Oct;22(5):589-96.PMID: 15485012 [PubMed - indexed for MEDLINE]Related articles

    17.

    Efficacy and tolerability of lumiracoxib 200 mg once daily for treatment of primary dysmenorrhea: results from two randomized controlled trials.

    Daniels S, Gitton X, Zhou W, Stricker K, Barton S.

    J Womens Health (Larchmt). 2008 Apr;17(3):423-37.PMID: 18373490 [PubMed - indexed for MEDLINE]Related articles

    18.

    Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout.

    Willburger RE, Mysler E, Derbot J, Jung T, Thurston H, Kreiss A, Litschig S, Krammer G, Tate GA.

    Rheumatology (Oxford). 2007 Jul;46(7):1126-32. Epub 2007 May 3.PMID: 17478464 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.

    Bingham CO 3rd, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S, Smugar SS, Fitzgerald BJ, O'Brien K, Tershakovec AM.

    Rheumatology (Oxford). 2007 Mar;46(3):496-507. Epub 2006 Aug 27.PMID: 16936327 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.

    Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS.

    Health Technol Assess. 2008 Apr;12(11):1-278, iii. Review.PMID: 18405470 [PubMed - indexed for MEDLINE]Related articlesFree article

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity